Description:
Phase Ib, open-label, dose-escalation clinical trial to evaluate the best-tolerated doses in
Acute Myeloid Leukaemia (AML) relapsed or refractory to chemotherapy.
This open-label, nonrandomized trial will comprise 2 stages. A dose escalation stage will
characterize the safety, tolerability and maximum tolerated dose (MTD), of OPB-111077.
Subsequently, an expansion stage will further evaluate the safety and antitumor activity of
OPB-111077 in AML relapsed or refractory to chemotherapy.
Enrollment to the expansion cohort will begin following determination of the MTD.
Approximately 6-12 patients will be included in the phase I part of this clinical trial.
Additional patients will be included in the expansion cohort up to a total of 15 patients.
The expansion cohort will serve to further evaluate safety simultaneously with preliminary
efficacy.
Patients will be selected and included in the study after testing the response to the drug
with the Vivia Biotech ex vivo CDx PharmaFlow PM test. PharmaFlow PM test is a companion
diagnostic (CDx) tool that provides a complete pharmacological profile for each individual,
allowing the detection of patients resistant to OPB-111077 and enriching the study in
patients that respond to the drug. The third of patients more sensitive to OPB-11077 wil be
included in the study.
Title
- Brief Title: Clinical Trial of OPB-111077 in Patients With Relapsed or Refractory Acute Myeloid Leukaemia
- Official Title: Phase Ib Clinical Trial of OPB-111077 in Patients With Relapsed or Refractory Acute Myeloid Leukaemia
Clinical Trial IDs
- ORG STUDY ID:
FDO-LMA-2016-01
- SECONDARY ID:
2016-004135-21
- NCT ID:
NCT03197714
Conditions
Interventions
Drug | Synonyms | Arms |
---|
OPB-111077 | | OPB-111077 |
Purpose
Phase Ib, open-label, dose-escalation clinical trial to evaluate the best-tolerated doses in
Acute Myeloid Leukaemia (AML) relapsed or refractory to chemotherapy.
This open-label, nonrandomized trial will comprise 2 stages. A dose escalation stage will
characterize the safety, tolerability and maximum tolerated dose (MTD), of OPB-111077.
Subsequently, an expansion stage will further evaluate the safety and antitumor activity of
OPB-111077 in AML relapsed or refractory to chemotherapy.
Enrollment to the expansion cohort will begin following determination of the MTD.
Approximately 6-12 patients will be included in the phase I part of this clinical trial.
Additional patients will be included in the expansion cohort up to a total of 15 patients.
The expansion cohort will serve to further evaluate safety simultaneously with preliminary
efficacy.
Patients will be selected and included in the study after testing the response to the drug
with the Vivia Biotech ex vivo CDx PharmaFlow PM test. PharmaFlow PM test is a companion
diagnostic (CDx) tool that provides a complete pharmacological profile for each individual,
allowing the detection of patients resistant to OPB-111077 and enriching the study in
patients that respond to the drug. The third of patients more sensitive to OPB-11077 wil be
included in the study.
Detailed Description
The optimal management of relapsed AML in patients who are not candidates for HSCT has yet to
be delineated. Given the median age at which AML is diagnosed and the high incidence of
relapse and significant toxicities associated with standard intensive remission induction
chemotherapy, new treatment options are needed to optimize AML outcomes. Changes on
metabolism are critical in Acute Myeloid Leukaemia (AML); besides, leukemic cells have high
requirements of energy and high basal metabolism. For this reason we hypothesized that
deregulations of energy metabolism and mitochondria could play a central role in AML.
OPB-111077, a novel low-molecular-weight compound discovered by Otsuka Pharmaceutical Co,
Ltd, is a new class drug targeting cancer cell metabolisms and STAT3 and is being developed
as an orally active antitumor agent for the treatment of various cancers. Sufficient
preclinical studies have shown its activity in several types of tumors and especially in AML.
Although in a phase I study their activity has been small in a group solid tumor, we may
hypostatize that this drug could be more efficient in tumor cells with a high proliferative
index as AML.
This is an open-label, phase Ib dose-escalation clinical trial to evaluate the safety and
tolerability of oral OPB-111077 in AML relapsed or refractory to chemotherapy patients.
OPB-111077 will be administered orally on a once daily dose schedule.
This open-label, nonrandomized trial will comprise 2 stages. A dose escalation stage will
characterize the safety, tolerability and MTD, of OPB-111077. Subsequently, an expansion
stage will further evaluate the safety and antitumor activity of OPB-111077 in AML relapsed
or refractory to chemotherapy. The overall response rate of OPB-11077 in acute myeloid
leukemia and its correlation with the ex-vivo PharmaFlow PM test will be also assessed.
Enrollment to the expansion cohort will begin following determination of the MTD.
OPB-111077 recommended dose for expansion cohort will be defined during the phase I as MTD.
Intra patient dose escalation is not allowed at any time of the study.
Patients will be included in the study upon signed informed consent and will follow study
procedures.
Two dose schemas will be employed:
- Level 1: 200 mg daily
- Level 2: 250 mg daily The starting dose level of oral OPB-111077 will be 200 mg od. A 3
+ 3 dose-escalation scheme will be used.
A minimum of 3 patients will be initially enrolled per cohort. DLTs will be assessed during
the DLT assessment window of 28 days following the first dose of OPB-111077. Patients who
withdraw or are withdrawn from the study prior to completing the DLT assessment window for
reasons other than a DLT will not be considered evaluable for DLT and will be replaced.
DLTs will be assessed during the DLT assessment window of 28 days following the first dose of
OPB-111077. Patients who withdraw or are withdrawn from the study prior to completing the DLT
assessment window for reasons other than a DLT will not be considered evaluable for DLT and
will be replaced.
Trial Arms
Name | Type | Description | Interventions |
---|
OPB-111077 | Experimental | Level 1: 200 mg daily Level 2: 250 mg daily | |
Eligibility Criteria
Inclusion Criteria:
- Patients at least 18 years old.
- Patients diagnosed of non M3 acute myeloid leukemia in relapse after intensive
chemotherapy.
- Patients with a highest sensitivity (higher 70% of the samples analyzed) in the bone
marrow analysis of the OPB-111077 ex-vivo sensitivity test.
- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.
- Bilirubin ≤ 2 × Upper Limit of Normal (ULN). For subjects with known Gilbert's
disease, bilirubin ≤ 3.0 mg/dL.
- Serum creatinine ≤2 × ULN or creatinine clearance (CrCl) ≥ 40 mL/min.
- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN.
- Left Ventricular Ejection Fraction (LVEF) must be equal to or greater than 50%.
- New York Heart Association (NYHA) congestive heart failure (CHF) class II or better.
- Recovery from adverse effects of prior therapy at time of enrollment to ≤ Grade 1
(excluding alopecia).
- Life expectancy ≥3 months
- Patients, or appropriate designee, must be able to provide informed consent.
Exclusion Criteria:
- Individuals with a history of other malignancies.
- Subject has uncontrolled intercurrent illness that would limit compliance with study
requirements.
- Patients diagnosed of M3/Acute promyelocytic leukemia (APL).
- The subject has received systemic antineoplastic therapy within 14 days of study
treatment.
- The subject has received any investigational agent within 28 days before the first
dose of study treatment.
- The subject has not recovered to baseline or CTCAE ≤ Grade 1 from toxicity due to all
prior therapies except alopecia and other non-clinically significant Adverse Events
(AEs).
- The subject has concurrent uncompensated hypothyroidism or thyroid dysfunction within
7 days before the first dose of study treatment.
- Gastrointestinal disorders particularly those associated with a high risk of
perforation or fistula formation.
- Malabsorption syndrome.
- Subject is unable to swallow capsules or tablets.
- Subject is pregnant or breastfeeding.
- Patients with history of allergic reactions attributed to components of OPB- 111077
that are not easily managed
- Subject has systemic infection requiring IV antibiotic therapy within 7 days preceding
the first dose of study drug, or other severe infection.
- Uncontrolled intercurrent illness that would limit compliance with study requirements.
- Patients with serious medical or psychiatric illness likely to interfere with
participation in this clinical study.
Maximum Eligible Age: | N/A |
Minimum Eligible Age: | 18 Years |
Eligible Gender: | All |
Healthy Volunteers: | No |
Primary Outcome Measures
Measure: | Dose-limiting toxicity (DLT) of OPB-111077 in patients with in acute myeloid Leukemia. |
Time Frame: | 28 days |
Safety Issue: | |
Description: | Any adverse event related to the study drug that occurred during the first cycle and considered relevant:
Any Grade 3 or 4 non-hematologic toxicity
Any unexpected non-tolerable grade II adverse event possibly related to the treatment regimen that requires delay beyond 1 week until recovery
Hematological toxicity is not considered doses limiting due to the characteristic of Acute Myeloid Leukemia. |
Secondary Outcome Measures
Measure: | Overall response rate. |
Time Frame: | Up to 8 months |
Safety Issue: | |
Description: | Percentage of patients to reach complete remission (CR), morphologic complete remission with incomplete blood count recovery (Cri) or partial remission (PR) according to Cheson et al criteria. |
Measure: | Overall response rate according to IC50 |
Time Frame: | Up to 8 months |
Safety Issue: | |
Description: | Percentage of patients to reach overall response rate according to IC50. |
Measure: | Overall response rate according to Area under de Curve |
Time Frame: | Up to 8 months |
Safety Issue: | |
Description: | Percentage of patients to reach overall response rate according to area under the curve. |
Measure: | Incidence of Treatment-Emergent Adverse Events |
Time Frame: | Up to 8 months |
Safety Issue: | |
Description: | Number of events per patient according to NCI CTCAE vs 4.03 |
Measure: | Progression Free Survival |
Time Frame: | Up to 8 months |
Safety Issue: | |
Description: | Time from the date of informed consent form to the date of progression or death (from any cause), whichever occurs first |
Measure: | Overall Survival |
Time Frame: | Up to 12 months |
Safety Issue: | |
Description: | Time from the date of informed consent form to the date of death due to any cause |
Details
Phase: | Phase 1 |
Primary Purpose: | Interventional |
Overall Status: | Completed |
Lead Sponsor: | Hospital Universitario 12 de Octubre |
Trial Keywords
Last Updated
February 15, 2021